A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Pazopanib (Primary) ; Docetaxel; Gemcitabine
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 29 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 29 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 2 Mar 2018.
- 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.